Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1097/MJT.0000000000000644 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Signal detection of immune thrombocytopenia associated with immune checkpoint inhibitors.
Sci Rep
October 2024
Department of Oncology, The Sixth Affiliated Hospital, School of Medicine, South China University of Technology, Foshan, 528200, Guangdong, People's Republic of China.
Article Synopsis
- Immune checkpoint inhibitors (ICIs) are important cancer treatments, but they can cause immune-related adverse events (irAEs) like skin rashes, pneumonitis, and rare cases of immune thrombocytopenia, which can lead to severe bleeding.
- A study analyzed data from the FDA Adverse Event Reporting System (FAERS) from 2011 to 2023 and found 404 reports of immune thrombocytopenia linked to various ICIs, revealing that it was associated with all ICIs except one.
- The onset of thrombocytopenia varied depending on the type of inhibitor, with PD-1 inhibitors causing it most frequently, and the condition was found to be more common in males, older individuals
Atezolizumab-Induced Lambert-Eaton Myasthenic Syndrome in a Patient With Small-Cell Lung Cancer.
Cureus
January 2023
Neurology, Hakodate Municipal Hospital, Hakodate, JPN.
The case of a 70-year-old man who developed Lambert-Eaton myasthenic syndrome (LEMS) while receiving treatment for extensive-stage small-cell lung cancer (SCLC) is presented. He started receiving maintenance immunotherapy with atezolizumab following four cycles of combination therapy with , carboplatin, and etoposide. After five cycles of maintenance therapy, he complained of muscle weakness in the lower limbs and fatigue.
View Article and Find Full Text PDFAtezolizumab induced new-onset type 1 diabetes mellitus.
J Oncol Pharm Pract
July 2023
Endocrinology Department, Hospital Universitario de Navarra, Pamplona, Navarra, Spain.
Introduction: Immune checkpoint inhibitors (ICI) are novel therapeutic strategies in cancer treatment, promoting anti-tumor response by boosting cytotoxic T lymphocytes. Despite their high effectiveness, they can trigger the activation of diverse autoimmune diseases in genetically predisposed individuals. New-onset autoimmune diabetes mellitus type 1 (T1D) is an extremely unusual side effect, described in less than 1% of patients.
View Article and Find Full Text PDFAtezolizumab-induced autoimmune diabetes mellitus presenting as diabetic ketoacidosis and Takotsubo cardiomyopathy.
BMJ Case Rep
July 2022
Department of Hematology/Oncology, Crozer-Chester Medical Center, Upland, PA, USA
Atezolizumab is a humanised monoclonal IgG1 antibody that is used in treating many solid malignancies. Endocrinopathies are known but a rare adverse event of these immunotherapeutic drugs. Autoimmune diabetes induced by atezolizumab has been rarely reported in the literature.
View Article and Find Full Text PDFAtezolizumab-induced scleroderma: a rare complication.
BMJ Case Rep
November 2021
Department of Rheumatology, Allegheny Health Network, Pittsburgh, Pennsylvania, USA.
Few cases of programmed death-ligand 1 inhibitor-induced scleroderma have been reported and their clinical features remain unpublished. Optimal management is, therefore, unknown and an autoantibody association has yet to be identified. We present the case of a female in her 60s who developed skin thickening after starting atezolizumab for metastatic non-small cell lung cancer.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!